SG11201810758WA - Modification of engineered influenza hemagglutinin polypeptides - Google Patents

Modification of engineered influenza hemagglutinin polypeptides

Info

Publication number
SG11201810758WA
SG11201810758WA SG11201810758WA SG11201810758WA SG11201810758WA SG 11201810758W A SG11201810758W A SG 11201810758WA SG 11201810758W A SG11201810758W A SG 11201810758WA SG 11201810758W A SG11201810758W A SG 11201810758WA SG 11201810758W A SG11201810758W A SG 11201810758WA
Authority
SG
Singapore
Prior art keywords
international
sanofi pasteur
cambridge
pct
applicant
Prior art date
Application number
SG11201810758WA
Inventor
Tod Strugnell
Eliud Oloo
Raymond Oomen
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of SG11201810758WA publication Critical patent/SG11201810758WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111101111011101111111101011111001111111111111111111111111111101111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\") WO 2017/210592 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/005 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: PCT/US2017/035738 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: 02 June 2017 (02.06.2017) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/345,502 03 June 2016 (03.06.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: SANOFI PASTEUR INC. [US/US]; 1 Discov- ery Drive, Swiftwater, PA 18730 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: STRUGNELL, Tod; Sanofi Pasteur Inc., 38 Sidney Street, Cambridge, MA 02139 (US). 0E00, Eli- ud; Sanofi Pasteur Inc., 38 Sidney Street, Cambridge, MA 02139 (US). OOMEN, Raymond; Sanofi Pasteur Inc., 38 Sidney Street, Cambridge, MA 02139 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Agent: CHEN, Fangli et al.; Proskauer Rose LLP, One In- (74) _ ternational Place, Boston, MA 02110 (US). — = Title: MODIFICATION OF ENGINEERED INFLUENZA HEMAGGLUTININ POLYPEPTIDES = (54) = = = = = = = msri s — = i = _ , ' , i 7 .• , , = = .„, , ,-1 G63 -G277 V125 - G277 P135 - P269 ei 01 kr) © ,-, Fla 1 ei I r ----- (57) 1-1 : The present invention provides, among other things, modified recombinant HA polypeptides with broadened immuno- © genic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same. ei C [Continued on next page] WO 2017/210592 Al MIDEDIMOMMIMMEM001101011M101011HEVOIS Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the earlier application (Rule 4.17(iii)) priority of the Published: — with international search report (Art. 21(3))
SG11201810758WA 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides SG11201810758WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345502P 2016-06-03 2016-06-03
PCT/US2017/035738 WO2017210592A1 (en) 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides

Publications (1)

Publication Number Publication Date
SG11201810758WA true SG11201810758WA (en) 2018-12-28

Family

ID=59093612

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810758WA SG11201810758WA (en) 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides
SG10201913650WA SG10201913650WA (en) 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913650WA SG10201913650WA (en) 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides

Country Status (14)

Country Link
US (2) US11116832B2 (en)
EP (1) EP3464327A1 (en)
JP (3) JP7110119B2 (en)
KR (2) KR20230061583A (en)
CN (2) CN109563138B (en)
AU (2) AU2017275663B2 (en)
BR (1) BR112018075078A2 (en)
CA (1) CA3026094A1 (en)
EA (1) EA201892385A1 (en)
IL (1) IL263416A (en)
MA (1) MA45159A (en)
MX (2) MX2018014887A (en)
SG (2) SG11201810758WA (en)
WO (1) WO2017210592A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110106192B (en) * 2019-05-23 2021-11-12 广州医科大学 Highly pathogenic H7N9 avian influenza virus antigen with low receptor binding activity and preparation method thereof
CN110106193B (en) * 2019-05-23 2021-11-12 广州医科大学 Highly pathogenic H7N9 avian influenza virus antigen with low receptor binding activity and preparation method thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
ES2366201T3 (en) 1994-07-15 2011-10-18 University Of Iowa Research Foundation IMMUNMODULATING OLIGONUCLEOTIDES.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
ATE370740T1 (en) 1997-05-20 2007-09-15 Ottawa Health Research Inst METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP2581093B1 (en) 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
AU2007345768B2 (en) 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
WO2011044152A1 (en) * 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
KR101262300B1 (en) * 2009-10-06 2013-05-20 헬릭스 주식회사 Protein vaccine of high pathogenic avian influenza virus derived from transgenic plant and method for preparation thereof
WO2012036993A1 (en) 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
CN103458922B (en) 2011-01-31 2017-10-03 纳米医疗公司 Recombinant viral vector and method of the induction to the heterologous hypotype immune response of influenza A virus
CN103732749B (en) 2011-06-20 2017-03-29 高等教育联邦***-匹兹堡大学 The H1N1 influenza antigens of the width reactivity of calculation optimization
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CN103957891B (en) 2011-09-23 2017-01-11 ***合众国由健康及人类服务部部长代表 Novel influenza hemagglutinin protein-based vaccines
CN103221064B (en) * 2011-11-23 2014-12-03 苏州工业园区唯可达生物科技有限公司 Immune methods against influenza viruses and combinatorial vaccines thereof
MX2014009148A (en) * 2012-02-07 2014-09-22 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses.
IN2014DN05695A (en) * 2012-02-13 2015-05-15 Univ Pittsburgh
RU2017141447A (en) * 2012-03-30 2019-02-13 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн RECOMBINANT HEMAGLUGUTININ (HA) VIRUS INFLUENZA POLYPEPTIDES, COMPOSITIONS CONTAINING THEM, AND METHODS FOR CALLING AN IMMUNE RESPONSE REGARDING THE H1N1 INFLUENZA VIRUS
WO2014085616A1 (en) 2012-11-27 2014-06-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
KR20150104117A (en) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Influenza virus vaccines and uses thereof
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
EP3039036B1 (en) 2013-08-28 2019-05-22 GlaxoSmithKline Biologicals S.A. Novel influenza antigens and antibodies

Also Published As

Publication number Publication date
CA3026094A1 (en) 2017-12-07
CN115746107A (en) 2023-03-07
AU2017275663B2 (en) 2021-12-09
JP7110119B2 (en) 2022-08-01
US11116832B2 (en) 2021-09-14
US20200215182A1 (en) 2020-07-09
JP2020141703A (en) 2020-09-10
US11904012B2 (en) 2024-02-20
AU2017275663A1 (en) 2018-12-13
AU2022201514A1 (en) 2022-03-24
SG10201913650WA (en) 2020-03-30
CN109563138B (en) 2022-09-23
WO2017210592A1 (en) 2017-12-07
EP3464327A1 (en) 2019-04-10
MX2018014887A (en) 2019-06-06
JP2019525733A (en) 2019-09-12
JP7479424B2 (en) 2024-05-08
KR20190039065A (en) 2019-04-10
CN109563138A (en) 2019-04-02
AU2022201514B2 (en) 2024-02-15
BR112018075078A2 (en) 2019-03-06
EA201892385A1 (en) 2019-06-28
IL263416A (en) 2019-01-31
KR20230061583A (en) 2023-05-08
MX2023008256A (en) 2023-07-19
US20220054623A1 (en) 2022-02-24
MA45159A (en) 2019-04-10
JP2022153591A (en) 2022-10-12
KR102529010B1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201900269XA (en) Channel sensing for independent links
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909949XA (en) Targeted immunotolerance
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201804915RA (en) Methods for treating huntington's disease
SG11201810522UA (en) Anti-cd40 antibodies and their uses
SG11201907023UA (en) Method of reducing neutropenia
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201908075UA (en) A microneedle device
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901517YA (en) Wireless telecommunications methods and apparatus using system information value tag
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch